Company Description
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.
The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.
It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.
In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease.
CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
| Country | United States |
| Founded | 1983 |
| IPO Date | Jan 1, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Geert R. Kersten Esq. |
Contact Details
Address: 8229 Boone Blvd ., Suite 802 Vienna, Virginia 22182 United States | |
| Phone | (703) 506-9460 |
| Website | cel-sci.com |
Stock Details
| Ticker Symbol | CVM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000725363 |
| CUSIP Number | 150837607 |
| ISIN Number | US1508376076 |
| Employer ID | 84-0916344 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Geert R. Kersten Esq. | Chief Executive and Financial Officer, Treasurer and Director |
| Patricia B. Prichep | Senior Vice President of Operations and Corporate Secretary |
| Dr. Eyal Talor Ph.D. | Chief Scientific Officer |
| Dr. Daniel H. Zimmerman Ph.D. | Senior Vice President of Research and Cellular Immunology |
| John Cipriano | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 7, 2024 | ARS | Filing |
| Mar 7, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 14, 2024 | 10-Q | Quarterly Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 9, 2024 | 424B5 | Filing |
| Dec 22, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 21, 2023 | 10-K | Annual Report |
| Nov 20, 2023 | 8-K | Current Report |
| Nov 16, 2023 | 424B5 | Filing |